What Is Enzalutamide?
Enzalutamide is an oral prescription medicine used in the treatment of certain prostate cancers. It is an androgen-receptor inhibitor and belongs pharmacologically to the endocrine-therapy group of anticancer medicines.
The medicine is designed to interfere with androgen signaling. Androgens are male sex hormones, including testosterone, that can stimulate the growth and survival of prostate cancer cells. By blocking androgen-receptor activity, enzalutamide reduces the ability of these hormonal signals to drive prostate cancer progression.
The European Medicines Agency classifies enzalutamide under the therapeutic area of prostatic neoplasms and the pharmacotherapeutic group of endocrine therapy. Its ATC code is L02BB04.
Enzalutamide as a Targeted Hormonal Treatment
The term “hormonal treatment” can sometimes cause confusion. Enzalutamide is not a hormone itself. Instead, it interferes with the receptor that allows prostate cancer cells to respond to male hormones.
This distinction is important because prostate cancer can remain dependent on androgen-receptor signaling even when testosterone levels have already been reduced through androgen-deprivation therapy.
Enzalutamide therefore acts at the receptor-signaling level rather than simply attempting to reduce testosterone production.
Medicine Class
Enzalutamide is commonly described as an androgen-receptor signaling inhibitor or androgen-receptor antagonist.
Its therapeutic classification distinguishes it from:
- Conventional cytotoxic chemotherapy
- Radiation therapy
- Surgical treatment
- LHRH/GnRH androgen-deprivation medicines
- Immunotherapy
- PARP inhibitors
- CDK4/6 inhibitors
It can nevertheless be used alongside androgen-deprivation therapy when required by the applicable treatment regimen. Current EMA information specifies combination use with androgen-deprivation therapy for metastatic hormone-sensitive prostate cancer.
What Is Prostate Cancer?
Prostate cancer develops in the prostate gland, an organ in the male reproductive system. Some prostate cancers grow slowly, while others behave more aggressively and can spread beyond the prostate.
When prostate cancer spreads, it may involve lymph nodes, bones or other organs. Treatment depends on factors such as:
- Disease stage
- Tumor characteristics
- PSA level
- Previous treatment
- Whether the cancer has metastasized
- Whether the cancer remains hormone-sensitive
- Whether the cancer has become castration-resistant
- Overall health
- Other medical conditions
Enzalutamide is not appropriate for every prostate cancer patient. Its role depends on the clinical circumstances and applicable regulatory indication.
Hormone-Sensitive Prostate Cancer
Hormone-sensitive prostate cancer remains responsive to treatment that reduces or blocks androgen signaling.
In metastatic hormone-sensitive disease, current EMA information specifies enzalutamide in combination with androgen-deprivation therapy.
In certain high-risk biochemical recurrent non-metastatic hormone-sensitive prostate cancer settings, enzalutamide may be used as monotherapy or with androgen-deprivation therapy when patients are unsuitable for salvage radiotherapy.
Castration-Resistant Prostate Cancer
Castration-resistant prostate cancer refers to prostate cancer that progresses despite androgen-deprivation treatment or very low testosterone levels.
This does not mean that androgen signaling has become completely irrelevant. Prostate cancer cells can continue to use androgen-receptor pathways through mechanisms that allow signaling to persist despite reduced circulating testosterone.
Enzalutamide is designed to interfere with this receptor pathway.
Current EMA information includes both high-risk non-metastatic castration-resistant prostate cancer and several metastatic castration-resistant prostate cancer settings.
Enzamide 40 mg Product
The supplied website brief identifies the following product:
| Generic Medicine | Brand | Strength | Company | Main Medical Use |
|---|---|---|---|---|
| Enzalutamide | Enzamide | 40 mg | Everest | Specific prostate cancer treatment settings |
The table reflects the supplied product information. It should not be interpreted as independent confirmation of the product’s regulatory authorization or manufacturing details.
Reference Medicine
Xtandi is an established reference medicine containing enzalutamide. EMA documentation identifies Xtandi as a prescription cancer medicine for men with prostate cancer and lists Astellas Pharma Europe B.V. as the EU marketing authorization holder.
The existence of a reference medicine does not by itself establish that every branded enzalutamide product is manufactured by the same company.
40 mg Strength
A 40 mg product contains 40 mg of enzalutamide per dosage unit, assuming the product labeling confirms that strength and formulation.
The current EMA Xtandi product information includes 40 mg film-coated tablets, with each tablet containing 40 mg of enzalutamide.
The total amount prescribed per day is a separate issue. For the EMA reference product, the recommended dose is 160 mg once daily, administered as four 40 mg tablets or two 80 mg tablets.
Patients should never construct a daily dose themselves without a prescription.
How Enzalutamide Works
Enzalutamide interferes with androgen-receptor signaling. The androgen receptor is a protein that receives signals from testosterone and related hormones.
When activated, androgen receptors can influence gene expression that supports prostate cancer-cell growth and survival.
Enzalutamide blocks this signaling pathway, reducing androgen-driven stimulation of prostate cancer cells.
This mechanism explains why enzalutamide can remain useful even when prostate cancer has become resistant to conventional androgen-deprivation approaches.
Treatment Supervision
The medicine should be prescribed and monitored by a healthcare professional experienced in prostate cancer. EMA product information explicitly states that enzalutamide treatment should be initiated and supervised by specialist physicians.
Monitoring may include clinical assessment, PSA measurements and evaluation for adverse effects, depending on the patient’s treatment plan.
Important Safety Considerations
Patients should discuss relevant medical history before treatment, particularly:
- Previous seizures
- Neurological disorders
- Stroke
- Brain injury
- Cardiovascular disease
- Ischemic heart disease
- Falls or fracture risk
- Other serious medical conditions
Enzalutamide has clinically relevant interaction potential, so all medicines and supplements should be disclosed.
Summary
Enzalutamide is a targeted hormonal anticancer medicine used in defined prostate-cancer settings. It acts by blocking androgen-receptor signaling rather than directly destroying rapidly dividing cells like conventional chemotherapy.
The supplied product information identifies Enzamide 40 mg—Everest Pharmaceuticals Ltd.. Current regulatory information establishes enzalutamide’s role in several prostate-cancer treatment settings, while product-specific authorization and manufacturing information should be verified from appropriate documentation.